{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:19Z","timestamp":1791581899059,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373361,82172687"],"award-info":[{"award-number":["82373361,82172687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972186"],"award-info":[{"award-number":["81972186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373361"],"award-info":[{"award-number":["82373361"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172687"],"award-info":[{"award-number":["82172687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["25JCLMJC00010"],"award-info":[{"award-number":["25JCLMJC00010"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["112-2639-B-039-001-ASP"],"award-info":[{"award-number":["112-2639-B-039-001-ASP"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["112-2639-B-039-001"],"award-info":[{"award-number":["112-2639-B-039-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.canlet.2026.218283","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:08:13Z","timestamp":1770224893000},"page":"218283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy"],"prefix":"10.1016","volume":"643","author":[{"given":"Delong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-4385","authenticated-orcid":false,"given":"Riyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3498-7686","authenticated-orcid":false,"given":"Linlin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218283_bib1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2020.10.010","article-title":"Beyond kinases: targeting replication stress proteins in cancer therapy","volume":"7","author":"Baillie","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2026.218283_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218283_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218283_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218283_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/CCO.0000000000000867","article-title":"Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations","volume":"34","author":"Ngoi","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2026.218283_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218283_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2018.05.011","article-title":"Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR\/Chk1 targeting in medulloblastoma cells","volume":"430","author":"Kr\u00fcger","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218283_bib8","unstructured":"T.A. Yap, D.S.P. Tan, A. Stathis, G.I. Shapiro, M. Joerger, J. Zhang, R. Plummer, M.B. Sawyer, S.W. Tan, V. Castonguay, N.Y. Gabrail, N. Matsubara, Phase Ib Basket Expansion Trial and alternative-schedule dose-escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects, (n.d.).."},{"key":"10.1016\/j.canlet.2026.218283_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218283_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55637-5","article-title":"KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A de fi ciency","author":"Awwad","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib12","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ccell.2025.06.011","article-title":"KEAP1 and STK11\/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer","author":"Galan-Cobo","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218283_bib13","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218283_bib14","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218283_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218283_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.06.010","article-title":"The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma","volume":"432","author":"Shi","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218283_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embj.2019104036","article-title":"ATR inhibition potentiates ionizing radiation\u2010induced interferon response via cytosolic nucleic acid\u2010sensing pathways","volume":"39","author":"Feng","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2026.218283_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado4618","article-title":"ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer","volume":"10","author":"Taniguchi","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218283_bib20","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218283_bib21","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218283_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib23","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218283_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl9330","article-title":"ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume":"7","author":"Hsieh","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218283_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218283_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-51236-6","article-title":"Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1-and anti-NKG2A-based adjuvant immunotherapy","author":"Patin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.20182041","article-title":"Sweetening the hallmarks of cancer: galectins as multifunctional mediators of tumor progression","volume":"217","author":"Girotti","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218283_bib29","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib30","first-page":"1","volume":"3","author":"Karkempetzaki","year":"2025"},{"key":"10.1016\/j.canlet.2026.218283_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-61822-x","article-title":"Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target","volume":"16","author":"Lla\u00f3-Cid","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218283_bib32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218283_bib33","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218283_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-008984","article-title":"Do galectins serve as soluble ligands for immune checkpoint receptors?","volume":"12","author":"Torres","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218283_bib35","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1084\/jem.20132687","article-title":"Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies","volume":"211","author":"Madireddi","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218283_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm.4314","article-title":"Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance","volume":"23","author":"Daley","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218283_bib37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.immuni.2014.06.011","article-title":"Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells","volume":"41","author":"Wu","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218283_bib38","first-page":"OF1","article-title":"Single-cell eQTL mapping reveals cell subtype\u2013specific genetic control and mechanism in malignant transformation of colorectal cancer","author":"Chen","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218283_bib39","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1002\/jcp.29309","article-title":"Molecular and clinical characterization of Galectin-9 in glioma through 1,027 samples","volume":"235","author":"Yuan","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2026.218283_bib40","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1038\/s41388-020-1186-7","article-title":"Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels","volume":"39","author":"Seifert","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218283_bib41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijbs.79852","article-title":"Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity","volume":"19","author":"Zheng","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2026.218283_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010926","article-title":"Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion","volume":"13","author":"Linghu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218283_bib43","doi-asserted-by":"crossref","unstructured":"A. Filipovic, Z. Wainber, J. Wang, J. Bendell, F. Janku, M. Sharma, A. Mahipal, J. Bolen, E. Elenko, C. Korth, G. Dranitsaris, Phase1\/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors, 9 (2021) A512\u2013A512. https:\/\/doi.org\/10.1136\/jitc-2021-sitc2021.482. .","DOI":"10.1136\/jitc-2021-SITC2021.482"},{"key":"10.1016\/j.canlet.2026.218283_bib44","first-page":"2363","article-title":"PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation","volume":"12","author":"Xue","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218283_bib45","series-title":"Open Access GSVA : Gene Set Variation Analysis for Microarray and RNA-seq Data","author":"Sonja","year":"2013"},{"key":"10.1016\/j.canlet.2026.218283_bib46","first-page":"1739","volume":"27","author":"Liberzon","year":"2011"},{"key":"10.1016\/j.canlet.2026.218283_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218283_bib48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","article-title":"Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy","volume":"36","author":"Lechner","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2026.218283_bib49","first-page":"1","article-title":"Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies","volume":"118","author":"Li","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218283_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218283_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.165615","article-title":"The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy","volume":"8","author":"Vendetti","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218283_bib52","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218283_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218283_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010791","article-title":"Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice","volume":"13","author":"Fauvre","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218283_bib55","article-title":"Combinatorial inhibition of Galectin-9 and CHK1 represent a novel treatment strategy for T-Cell acute lymphoblastic leukemia","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218283_bib56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1 + PD-1 + CD8 + T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218283_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216043","article-title":"CD8+ T cell exhaustion and cancer immunotherapy","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218283_bib58","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218283_bib59","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","article-title":"The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake","volume":"54","author":"de Mingo Pulido","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218283_bib60","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.1c00902","article-title":"Galectin-9 signaling drives breast cancer invasion through extracellular matrix","author":"Pally","year":"2022","journal-title":"ACS Chem. Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:42:52Z","timestamp":1778539372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":60,"alternative-id":["S0304383526000467"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218283","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218283"}}